tradingkey.logo

Revvity Inc

RVTY

88.230USD

+0.330+0.38%
收盘 08/01, 16:00美东报价延迟15分钟
10.40B总市值
36.29市盈率 TTM

Revvity Inc

88.230

+0.330+0.38%
关于 Revvity Inc 公司
Revvity, Inc. 是一家健康科学解决方案、技术和服务提供商,提供从发现到开发、从诊断到治疗的工作流程。其部门包括生命科学和诊断。生命科学部门提供面向生命科学市场的产品和服务。生命科学部门的应用包括 MicroBeta、MuviCyte 活细胞成像系统、Signals Image Artist、VICTOR Nivo 多模式平板读取器台式系统、EnSight 多模式平板读取器台式系统、BioLegend LEGENDplex 基于珠子的试剂和 Quantum GX2 系统。其诊断部门开发诊断、工具和应用程序,专注于生殖健康、免疫诊断和应用基因组学市场的临床导向客户。它为医院和医疗实验室提供仪器、试剂、检测平台和软件。它专注于生殖健康、免疫诊断和新兴市场诊断。
公司简介
公司代码RVTY
公司名称Revvity Inc
上市日期Jul 06, 1965
成立日期1947
CEODr. Prahlad R. Singh, Ph.D.
员工数量11000
证券类型Ordinary Share
年结日Jul 06
公司地址77 4Th Avenue
城市WALTHAM
上市交易所NYSE Consolidated
国家United States of America
邮编02451
电话17816636900
网址https://www.revvity.com/
公司代码RVTY
上市日期Jul 06, 1965
成立日期1947
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Prahlad R. Singh, Ph.D.
Dr. Prahlad R. Singh, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
106.26K
+17.81%
Mr. Alexandros P. (Alexis) Michas
Mr. Alexandros P. (Alexis) Michas
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
45.44K
+6.67%
Mr. Joel S. Goldberg
Mr. Joel S. Goldberg
Senior Vice President - Administration, General Counsel, Secretary
Senior Vice President - Administration, General Counsel, Secretary
37.69K
+12.84%
Dr. Peter Barrett, Ph.D.
Dr. Peter Barrett, Ph.D.
Independent Director
Independent Director
26.01K
+10.22%
Mr. Maxwell Krakowiak
Mr. Maxwell Krakowiak
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
23.36K
+628.47%
Mr. Tajinder S. Vohra
Mr. Tajinder S. Vohra
Senior Vice President - Global Operations
Senior Vice President - Global Operations
22.63K
+137.66%
Ms. Miriame Victor
Ms. Miriame Victor
Chief Commercial Officer, Senior Vice President
Chief Commercial Officer, Senior Vice President
14.29K
+61.74%
Ms. Pascale Witz
Ms. Pascale Witz
Independent Director
Independent Director
13.71K
+21.36%
Mr. Michael A. Klobuchar
Mr. Michael A. Klobuchar
Independent Director
Independent Director
5.09K
+90.13%
Dr. Sophie V. Vandebroek, Ph.D.
Dr. Sophie V. Vandebroek, Ph.D.
Independent Director
Independent Director
5.09K
+90.13%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Prahlad R. Singh, Ph.D.
Dr. Prahlad R. Singh, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
106.26K
+17.81%
Mr. Alexandros P. (Alexis) Michas
Mr. Alexandros P. (Alexis) Michas
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
45.44K
+6.67%
Mr. Joel S. Goldberg
Mr. Joel S. Goldberg
Senior Vice President - Administration, General Counsel, Secretary
Senior Vice President - Administration, General Counsel, Secretary
37.69K
+12.84%
Dr. Peter Barrett, Ph.D.
Dr. Peter Barrett, Ph.D.
Independent Director
Independent Director
26.01K
+10.22%
Mr. Maxwell Krakowiak
Mr. Maxwell Krakowiak
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
23.36K
+628.47%
Mr. Tajinder S. Vohra
Mr. Tajinder S. Vohra
Senior Vice President - Global Operations
Senior Vice President - Global Operations
22.63K
+137.66%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Product
562.68M
84.64%
Service
102.08M
15.36%
地区USD
名称
营收
占比
Americas
304.63M
45.83%
Europe
181.79M
27.35%
Asia
178.34M
26.83%
业务
地区
业务USD
名称
营收
占比
Product
562.68M
84.64%
Service
102.08M
15.36%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
19.10%
The Vanguard Group, Inc.
12.16%
T. Rowe Price Associates, Inc.
7.96%
BlackRock Institutional Trust Company, N.A.
5.15%
Janus Henderson Investors
5.09%
Other
50.54%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
19.10%
The Vanguard Group, Inc.
12.16%
T. Rowe Price Associates, Inc.
7.96%
BlackRock Institutional Trust Company, N.A.
5.15%
Janus Henderson Investors
5.09%
Other
50.54%
股东类型
持股股东
占比
Investment Advisor
69.85%
Investment Advisor/Hedge Fund
21.16%
Hedge Fund
2.47%
Pension Fund
1.65%
Research Firm
1.35%
Bank and Trust
1.33%
Sovereign Wealth Fund
1.02%
Individual Investor
0.32%
Family Office
0.05%
Other
0.79%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1195
116.79M
99.09%
-3.51M
2025Q1
1255
117.73M
99.83%
-3.82M
2024Q4
1277
114.54M
95.28%
-3.97M
2024Q3
1253
112.35M
91.11%
-5.77M
2024Q2
1249
112.44M
91.13%
-1.63M
2024Q1
1287
107.57M
87.09%
-8.24M
2023Q4
1315
109.29M
88.55%
-2.41M
2023Q3
1347
106.10M
85.47%
-6.10M
2023Q2
1383
106.88M
85.21%
-9.65M
2023Q1
1406
108.31M
85.69%
-5.19M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
22.52M
19.1%
+1.75M
+8.45%
Mar 31, 2025
The Vanguard Group, Inc.
14.33M
12.16%
+92.07K
+0.65%
Mar 31, 2025
T. Rowe Price Associates, Inc.
9.39M
7.96%
+1.93M
+25.90%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.07M
5.15%
+59.41K
+0.99%
Mar 31, 2025
Janus Henderson Investors
5.99M
5.09%
-364.31K
-5.73%
Mar 31, 2025
EdgePoint Investment Group Inc.
5.36M
4.55%
+1.30M
+32.10%
Mar 31, 2025
State Street Global Advisors (US)
5.17M
4.38%
+1.66K
+0.03%
Mar 31, 2025
Mitsubishi UFJ Asset Management Co., Ltd.
3.44M
2.92%
+62.31K
+1.84%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.99M
2.54%
+92.26K
+3.18%
Mar 31, 2025
Capital Research Global Investors
2.84M
2.41%
-152.06K
-5.09%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7 小时前
更新时间: 7 小时前
机构名称
占比
Otter Creek Focus Strategy ETF
2.35%
First Trust Indxx Medical Devices ETF
1.89%
T Rowe Price Capital Appreciation Equity ETF
1.69%
Invesco S&P 500 Equal Weight Health Care ETF
1.67%
VanEck Morningstar SMID Moat ETF
1.23%
ROBO Global Healthcare Technology & Innovation ETF
1.09%
Simplify Health Care ETF
1.07%
Pacer US Export Leaders ETF
0.98%
Janus Henderson US Sustainable Equity ETF
0.88%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.85%
查看更多
Otter Creek Focus Strategy ETF
占比2.35%
First Trust Indxx Medical Devices ETF
占比1.89%
T Rowe Price Capital Appreciation Equity ETF
占比1.69%
Invesco S&P 500 Equal Weight Health Care ETF
占比1.67%
VanEck Morningstar SMID Moat ETF
占比1.23%
ROBO Global Healthcare Technology & Innovation ETF
占比1.09%
Simplify Health Care ETF
占比1.07%
Pacer US Export Leaders ETF
占比0.98%
Janus Henderson US Sustainable Equity ETF
占比0.88%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
占比0.85%
分红派息
近5年累计派现 168.35M 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Oct 24, 2024
RVTY.NB Final Cash Dividend of gross USD 0.07 paid on Feb 07, 2025 going ex on Jan 17, 2025
Jan 17, 2025
Feb 07, 2025
Jan 17, 2025
Jul 25, 2024
RVTY.NB Final Cash Dividend of gross USD 0.07 paid on Nov 08, 2024 going ex on Oct 18, 2024
Oct 18, 2024
Nov 08, 2024
Oct 18, 2024
Apr 25, 2024
RVTY.NB Interim Cash Dividend of gross USD 0.07 paid on Aug 09, 2024 going ex on Jul 19, 2024
Jul 19, 2024
Aug 09, 2024
Jul 19, 2024
Jan 25, 2024
RVTY.NB Interim Cash Dividend of gross USD 0.07 paid on May 10, 2024 going ex on Apr 18, 2024
Apr 19, 2024
May 10, 2024
Apr 18, 2024
Oct 26, 2023
RVTY.NB Interim Cash Dividend of gross USD 0.07 paid on Feb 09, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Feb 09, 2024
Jan 18, 2024
Jul 21, 2023
RVTY.NB Final Cash Dividend of gross USD 0.07 paid on Nov 10, 2023 going ex on Oct 19, 2023
Oct 20, 2023
Nov 10, 2023
Oct 19, 2023
Apr 25, 2023
RVTY.NB Interim Cash Dividend of gross USD 0.07 paid on Aug 11, 2023 going ex on Jul 20, 2023
Jul 21, 2023
Aug 11, 2023
Jul 20, 2023
Jan 26, 2023
RVTY.NB Interim Cash Dividend of gross USD 0.07 paid on May 12, 2023 going ex on Apr 20, 2023
Apr 21, 2023
May 12, 2023
Apr 20, 2023
Oct 27, 2022
RVTY.NB Interim Cash Dividend of gross USD 0.07 paid on Feb 10, 2023 going ex on Jan 19, 2023
Jan 20, 2023
Feb 10, 2023
Jan 19, 2023
Jul 22, 2022
RVTY.NB Final Cash Dividend of gross USD 0.07 paid on Nov 11, 2022 going ex on Oct 20, 2022
Oct 21, 2022
Nov 11, 2022
Oct 20, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有
KeyAI